HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Downregulation of the proteasome subunits, transporter, and antigen presentation in hepatocellular carcinoma, and their restoration by interferon-gamma.

AbstractBACKGROUND:
In our previous study, expressions of human histocompatibility leukocyte antigens class I molecules (HLA-I) and the transporter associated with antigen processing (TAP) 1/2 genes were investigated in seven hepatocellular carcinoma (HCC) cell lines. Two cell lines, Hep-3B and HuH-7, showed a reduced level of TAP, which might cause the low surface expression of HLA-I. In order to understand the downregulation mechanism of antigen presentation in tumors, the two cell lines were further investigated.
METHODS:
Expressions of HLA-I and antigen presentation-related genes were analyzed by flow cytometry and polymerase chain reaction, respectively. Antigen presentation was tested in 51Cr-release assays.
RESULTS:
Flow cytometric analyses revealed low surface expression of HLA-I on Hep-3B and HuH-7 cells. Introduction of HLA-A2 gene did not result in a high surface expression of HLA-A2. This suggested the downregulation of HLA-I expression might be related to defects in the antigen presentation machinery. We then examined expression levels of various antigen presentation-related genes. Hep-3B and HuH-7 demonstrated low expression of the low-molecular-weight protein (LMP) 2, LMP7, TAP1, and HLA-I heavy-chain transcripts. The downregulation of these genes was dissolved by treatment with gamma-interferon. Furthermore, allo-specific cytotoxic T lymphocyte (CTL) lines failed to recognize Hep-3B and HuH-7 cells, while they killed IFN-gamma-treated Hep-3B and HuH-7 cells.
CONCLUSIONS:
Our results suggest that defects in the antigen presentation-related molecules might cause downregulation of HLA-I expression, antigen presentation, and subsequently, escape from specific CTL killing. The downregulation could be restored by IFN-gamma treatment, suggesting the potential use of IFN-gamma for therapeutic purposes.
AuthorsMasanori Matsui, Sanae Machida, Teru Itani-Yohda, Toshitaka Akatsuka
JournalJournal of gastroenterology and hepatology (J Gastroenterol Hepatol) Vol. 17 Issue 8 Pg. 897-907 (Aug 2002) ISSN: 0815-9319 [Print] Australia
PMID12164966 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents
  • HLA-A2 Antigen
  • Histocompatibility Antigens Class I
  • Membrane Transport Proteins
  • Multienzyme Complexes
  • Interferon-gamma
  • Cysteine Endopeptidases
  • Proteasome Endopeptidase Complex
Topics
  • Antigen Presentation (genetics)
  • Antineoplastic Agents (therapeutic use)
  • Carcinoma, Hepatocellular (drug therapy, genetics)
  • Cysteine Endopeptidases (genetics)
  • Down-Regulation (genetics)
  • HLA-A2 Antigen (genetics)
  • Histocompatibility Antigens Class I (genetics)
  • Humans
  • In Vitro Techniques
  • Interferon-gamma (genetics, therapeutic use)
  • Liver Neoplasms (drug therapy, genetics)
  • Membrane Transport Proteins (genetics)
  • Multienzyme Complexes (genetics)
  • Proteasome Endopeptidase Complex
  • Tumor Cells, Cultured

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: